Medical Cannabis: 60+ Companies Are Advancing Cannabinoid-Based Drug Development

Medical cannabis is moving into a more pharmaceutical-focused phase. Instead of relying only on cannabis-derived oils and wellness products, developers are investigating standardized cannabinoid formulations, defined doses and targeted therapeutic applications.

A 2026 pipeline analysis identified more than 60 companies developing over 65 medical cannabis drug candidates at different stages of development. The pipeline includes programmes targeting pain, neurological disorders, sleep conditions, inflammatory diseases and other indications. These figures reflect the scope of that particular analysis, rather than a complete count of every cannabinoid research programme worldwide.

Download Customized Sample Report: https://www.towardshealthcare.com/download-sample/5099 

Companies identified include Avicanna, Ananda Scientific, Artelo Biosciences, Neurotech International, Cardiol Therapeutics, Incannex Healthcare, Botanix Pharmaceuticals, InMed Pharmaceuticals, SciSparc and MIRA Pharmaceuticals. Their programmes illustrate the range of approaches being explored, from plant-derived cannabinoids to synthetic compounds and endocannabinoid-system targets.

What Is Changing in Medical Cannabis Drug Development?

1. Clinical research is becoming more indication-specific

Developers are investigating cannabinoids for conditions such as chronic pain, epilepsy, neurological disorders, chemotherapy-induced peripheral neuropathy and inflammatory diseases.

The commercial challenge is to establish reliable clinical evidence for each indication. Results from one cannabinoid formulation or patient population cannot automatically be applied to another.

2. Formulation technologies are gaining importance

Cannabinoid developers are working on oral capsules, oils, topical preparations, soft gels and other delivery systems. These technologies can influence absorption, bioavailability, dose consistency and patient adherence.

Companies that can improve the delivery of poorly water-soluble cannabinoids may create valuable formulation and licensing opportunities.

3. Pharmaceutical-grade manufacturing is becoming a competitive requirement

Drug developers need consistent cannabinoid composition, validated analytical methods, impurity controls, batch-to-batch reproducibility and appropriate manufacturing standards.

This creates opportunities for contract development and manufacturing organizations (CDMOs), active pharmaceutical ingredient suppliers, analytical testing laboratories and formulation specialists.

4. Regulatory developments are changing the U.S. landscape

On April 23, 2026, the U.S. Department of Justice announced that FDA-approved marijuana products and qualifying products covered by state medical marijuana licences would be placed in Schedule III of the Controlled Substances Act. The action does not amount to blanket federal legalization of cannabis. Broader rescheduling remains a separate regulatory process.

For pharmaceutical developers, the distinction matters. Regulatory classification, product approval, manufacturing permissions and state licensing can determine which development and commercialization routes are available.

Companies Developing Differentiated Cannabinoid Approaches

The competitive landscape includes companies pursuing different molecules, indications and delivery technologies.

These companies should not be compared only by the number of candidates in their pipelines. Clinical stage, trial design, intellectual property, regulatory status, manufacturing readiness and available capital provide a more meaningful assessment of their competitive positions.

Where Are the Business Opportunities?

1. Clinical pipeline and asset identification

Investors and pharmaceutical companies need to identify which cannabinoid candidates are progressing, which indications are being targeted and where clinical evidence is strongest. Tracking trial milestones, discontinued programmes and clinical partnerships can reveal potential licensing and acquisition opportunities.

2. Formulation and drug delivery partnerships

Companies with differentiated delivery technologies may become attractive partners for developers seeking better bioavailability, dose consistency or patient-friendly administration. Oral delivery, topical formulations and controlled-release technologies deserve particular attention.

3. API manufacturing and CDMO opportunities

Pharmaceutical-grade cannabinoid production requires quality controls, validated processes and reliable supply. Manufacturers with suitable extraction, purification, synthesis and analytical capabilities may find opportunities to serve drug developers.

4. Licensing, co-development and geographic expansion

Companies may seek partners to fund clinical trials, obtain regional development rights or support regulatory submissions. Pharmaceutical businesses can assess opportunities by comparing pipeline maturity, patent coverage, clinical evidence and local regulatory requirements.

5. Regulatory and commercialization intelligence

Cannabis regulations differ significantly across countries. Companies entering the United States, Canada, Europe or Asia-Pacific need to understand product classification, clinical-trial requirements, import and export controls, manufacturing standards and prescription pathways.

What Should Investors and Pharmaceutical Leaders Monitor?

The number of companies entering cannabinoid development does not necessarily indicate that all candidates will become commercially viable medicines. Several factors will separate stronger programmes from early-stage opportunities:

• Clinical evidence: Trial outcomes, patient populations, endpoints and reproducibility.

• Pipeline maturity: Phase progression, regulatory interactions and development timelines.

• Product differentiation: Cannabinoid composition, formulation, dosage and delivery technology.

• Intellectual property: Composition-of-matter patents, formulation protection and freedom to operate.

• Manufacturing readiness: API sourcing, GMP capabilities, quality systems and production scalability.

• Commercial partnerships: Licensing agreements, research collaborations and distribution arrangements.

For investors, these indicators can help distinguish companies with credible pharmaceutical development strategies from those primarily dependent on consumer cannabis sales.

How Towards Healthcare Supports Cannabinoid Intelligence

Towards Healthcare Research & Consulting helps life science decision-makers assess emerging therapeutic segments through structured competitive and strategic intelligence.

Relevant intelligence areas include:

• Complete Master Datasets: Company profiles, cannabinoid drug candidates, indications, clinical stages and development activity.

• Competitive Quadrants: Benchmarking companies based on pipeline strength, product differentiation, clinical progress and strategic positioning.

• Customized Dashboards: Tracking clinical milestones, company developments, partnerships and geographic activity.

• Pipeline Intelligence: Monitoring investigational candidates, trial progress and development changes.

• Buyer Identification: Identifying pharmaceutical manufacturers, CDMOs, API suppliers, investors and potential licensing partners.

• GTM Strategy: Assessing geographic opportunities, regulatory considerations and commercialization pathways.

The Strategic Outlook

Medical cannabis drug development is becoming more specialized. The next competitive advantage will depend less on the number of cannabinoid products a company offers and more on the quality of its clinical evidence, formulation technology, manufacturing capabilities and regulatory strategy.

For pharmaceutical leaders, manufacturers and investors, understanding the companies behind these programmes can help identify potential partnerships, pipeline assets and emerging commercial opportunities.

Explore cannabinoid drug developers, clinical pipeline activity and competitive intelligence with Towards Healthcare.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram